
Longeveron (LGVN) Stock Forecast & Price Target
Longeveron (LGVN) Analyst Ratings
Bulls say
Longeveron Inc. is positioned favorably due to its innovative approach in developing Lomecel-B, a stem cell formulation with demonstrated safety and potential in treating conditions like Hypoplastic Left Heart Syndrome, Alzheimer's disease, and Aging-related Frailty. The Phase 1b ELPIS I study indicated remarkable 5-year transplant-free survival rates of 100% in Stage II HLHS patients, significantly exceeding the historical standard of care at 80%, enhancing the prospects for FDA approval as the ongoing Phase 2b study progresses. Moreover, a revised discounted cash flow analysis suggests a substantial potential for growth, indicating a notable upside in the company's stock value based on the promising clinical data and innovative business model.
Bears say
Longeveron Inc.'s stock has depreciated approximately 56% year-to-date, largely attributed to the clinical development risks associated with its investigational product, Lomecel-B, particularly regarding unexpected safety signals in HLHS patients. Furthermore, there are concerns related to the efficacy outcomes from the ongoing ELPIS II study and potential delays in securing necessary funding for further clinical development. Additional risks include challenges in obtaining regulatory approval, slower-than-anticipated market penetration, as well as potential dilution risks that could undermine investor confidence and diminish share value.
This aggregate rating is based on analysts' research of Longeveron and is not a guaranteed prediction by Public.com or investment advice.
Longeveron (LGVN) Analyst Forecast & Price Prediction
Start investing in Longeveron (LGVN)
Order type
Buy in
Order amount
Est. shares
0 shares